New JID Publication Demontrates Bio-Me’s PMP™ Enabling Advanced Quantitative Skin Microbiome Research

Bio-Me, a leader in Microbiome Profiling, today announced having co-authored a new POC study in the Journal of Investigative Dermatology led by dsm-firmenich

OSLO, NORWAY, August 18, 2026 /EINPresswire.com/ -- Bio-Me, a leader in Precision Microbiome Profiling, today announced having co-authored a new proof-of-concept study in the Journal of Investigative Dermatology led by dsm-firmenich: “3-Dimensional Facial Skin Microbiome Mapping: An Integrated Technology for Continuous Visualization of Absolute Microbial Densities.”

The study demonstrates how absolute microbial quantification can be integrated with 3D spatial interpolation to generate continuous, high-resolution visualizations of bacterial and fungal distributions across the human face. According to the authors, this approach can help identify site-specific dysbioses, guide targeted interventions and track treatment effects, thereby linking microbial biogeography more directly to applied dermatology and skin health.

At the analytical core of the study, Bio-Me’s quantitative PCR-based Precision Microbiome Profiling platform, PMP™, was used to determine absolute abundances of 35 bacterial and fungal species/genera from facial skin samples. The paper further reports that PMP™-based quantification was validated by droplet digital PCR.

“This publication is a strong example of the type of high-quality, application-oriented skin microbiome research that our clients can achieve with PMP™,” said Dr. Ana Finzel, PMP™ product owner at Bio-Me and co-author. “For ingredient manufacturers, skincare developers and dermo-cosmetic brands, absolute quantification provides a more robust basis for understanding how specific microbial taxa vary across skin sites, respond to interventions and support product-relevant insights.”

Skin microbiome analysis is technically demanding because skin samples often contain low microbial biomass and substantial human background DNA. Bio-Me’s PMP™ platform is designed to address these challenges through targeted, sensitive and reproducible quantification of a wide range of defined microbial taxa. Its combination of absolute quantification, quantitative accuracy, precision, fast turnaround, and scalability makes PMP™ well suited for commercial R&D in skin, scalp and intimate care.

The DSM-Firmenich-led study revealed marked topographical heterogeneity in core facial microbial species, including distinct distribution patterns for Cutibacterium acnes and Malassezia restricta. The authors also showed that strategic selection of sampling sites may support comprehensive facial microbiome characterization while reducing participant burden and study costs.

For Bio-Me’s customers, the broader relevance of the publication is clear: advanced microbiome insights require robust quantitative data that can support more interpretable research, stronger product development decisions and more credible microbiome-related claim substantiation.
“We are proud to see PMP™ supporting client-led innovation at this level,” added Bio-Me CEO Dr. Arne Materna. “This study highlights how quantitative microbiome profiling can help translate complex skin microbiome signals into actionable R&D insights for the next generation of skincare and dermo-cosmetic innovation.”

For more information about Bio-Me’s PMP™ platform and microbiome analysis services, visit www.bio-me.com.

About Bio-Me:
Bio-Me is an Oslo-based biotechnology company specializing in high-resolution microbiome analysis. Its proprietary Precision Microbiome Profiling platform, PMP™, provides rapid, accurate and absolute quantification of a wide range of microbial taxa across gut, skin and vaginal microbiome applications. Bio-Me supports clients in skincare, intimate care, nutrition, healthcare and life sciences by translating complex microbiome biology into actionable quantitative insights.

Arne Materna
Bio-Me AS
+47 21 09 03 02
info@bio-me.com
Visit us on social media:
LinkedIn